AAV NRF2 gene therapy preserves retinal structure and function in rodent models of oxidative damage
Molecular Therapy · 2026-06 · 34 (6) · 3245-3269
DOI: 10.1016/j.ymthe.2026.02.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026-06. Verfasst von Apolonia Gardner und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Department of Ophthalmology, Harvard Medical School, Boston, MA 02115, USA; Ho…. Hauptthemen laut MEDLINE: Genetic Therapy, Genetic Vectors, Macular Degeneration, NF-E2-Related Factor 2. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Howard Hughes Medical Institute, Spark Therapeutics Inc, National Eye Institute.
Abstract (Originalsprache)
Dry age-related macular degeneration is the most frequent cause of visual impairment in individuals over age 50 in developed countries. It is characterized by deposits of oxidized proteins and lipids and results in progressive loss of high-acuity vision. One major risk factor is smoking, which causes oxidative stress in many tissues, including the eye. We previously showed that an adeno-associated viral vector expressing human NRF2 (AAV8/Best1-NRF2), a transcription factor that regulates responses to oxidative damage, slowed degeneration in mouse models of another blinding disorder, retinitis pigmentosa, which also includes oxidative stress. Here, our AAV8/Best1-NRF2 vector was tested in a model of oxidative stress wherein sodium iodate was injected systemically, as this is often used to model dry age-related macular degeneration. Sodium iodate causes acute oxidative damage to the retinal pigment epithelial cells, which provide support to the photoreceptor cells. In addition, this toxin ultimately leads to photoreceptor death. Subretinal injection of AAV8/Best1-NRF2 led to protection of the retinal pigment epithelium and photoreceptors, as well as preservation of visual function, in rat and mouse sodium iodate models. AAV8/Best1-NRF2 may serve as an effective gene-agnostic therapy for diseases with oxidative stress, including dry age-related macular degeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Department of Ophthalmology, Harvard Medical School, Boston, MA 02115, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; Program in…
- Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Department of Ophthalmology, Harvard Medical School, Boston, MA 02115, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
- Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA.
- Gene Therapy Research, Spark Therapeutics, Philadelphia, PA 19104, USA.
- Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Department of Ophthalmology, Harvard Medical School, Boston, MA 02115, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. Electronic…
Förderung
- Howard Hughes Medical Institute
- Spark Therapeutics Inc
- National Eye Institute
Zitieren
APA
Gardner, A., Wang, S., Daniels, A., Li, D., Wu, C., Lin, L., Hong, C., Zhao, S. R., Born, R. T., Kruczek, K., Weist, G., Barrio Real, L., Wicks, J., Nayal, M., Carter, A., Ott, C., Haurigot, V., & Cepko, C. L. (2026). AAV NRF2 gene therapy preserves retinal structure and function in rodent models of oxidative damage. Molecular Therapy, 34(6), 3245-3269. https://doi.org/10.1016/j.ymthe.2026.02.005
Vancouver
Gardner A, Wang S, Daniels A, Li D, Wu C, Lin L, et al. AAV NRF2 gene therapy preserves retinal structure and function in rodent models of oxidative damage. Molecular Therapy. 2026;34(6):3245-3269. doi:10.1016/j.ymthe.2026.02.005
BibTeX
@article{Gardner2026,
author = {Gardner, Apolonia and Wang, Shuai and Daniels, Adam and Li, Dan and Wu, Christine and Lin, Lucas and Hong, Christin and Zhao, Sophia R and Born, Richard T and Kruczek, Kamil and Weist, Genevieve and Barrio Real, Laura and Wicks, Joan and Nayal, Mohamad and Carter, Ashley and Ott, Christine and Haurigot, Virginia and Cepko, Constance L},
title = {AAV NRF2 gene therapy preserves retinal structure and function in rodent models of oxidative damage},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {6},
pages = {3245--3269},
doi = {10.1016/j.ymthe.2026.02.005}
}
EUVIMED